Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/33006
Tüm üstveri kaydı
Dublin Core AlanıDeğerDil
dc.contributor.authorTofighi, Mojdeh-
dc.contributor.authorBaillet, Georges-
dc.contributor.authorWeinmann, Pierre-
dc.contributor.authorMoretti, Jean Luc-
dc.date.accessioned2023-06-12T09:56:17Z-
dc.date.available2023-06-12T09:56:17Z-
dc.date.issued2004-02-28-
dc.identifier.citationTamgaç, F. vd. (2004). “The interest of (18)FDG-PET in the management of testicular cancer”. Presse Medicale, 33(4), 270-276.en_US
dc.identifier.issn0755-4982-
dc.identifier.urihttps://doi.org/10.1016/S0755-4982(04)98554-5-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0755498204985545-
dc.identifier.urihttp://hdl.handle.net/11452/33006-
dc.description.abstractThe key to prognosis initial staging and early recurrence diagnosis are key parameters in the treatment and outcome of testicular cancer. Initial staging. It is difficult using conventional modalities, which can miss node involvement and are non-specific since enlargement does not rime with involvement. (18)FDG PET improves the accuracy of initial staging. Residual mass and recurrences Existence of residual mass or enhancement of its volume in the presence of an otherwise beneficial chemotherapy is difficult to manage. Several studies have demonstrated the value of (18)FDG imaging in such cases. As for follow-up whole body (18)FDG can prevent multiple diagnostic imaging and can diagnose recurrences with greater diagnostic accuracy than with other imaging modalities.en_US
dc.language.isoenen_US
dc.publisherMasson Editeuren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGeneral and internal medicineen_US
dc.subjectPositron-emission-tomographyen_US
dc.subjectGerm-cell tumorsen_US
dc.subjectLymph-node metastasesen_US
dc.subjectAdvanced seminomaen_US
dc.subjectResidual massen_US
dc.subjectStage-Ien_US
dc.subjectFDG PETen_US
dc.subjectChemotherapyen_US
dc.subjectResectionen_US
dc.subjectTherapyen_US
dc.titleThe interest of (18)FDG-PET in the management of testicular canceren_US
dc.typeArticleen_US
dc.identifier.wos000189349600016tr_TR
dc.identifier.scopus2-s2.0-1442314360tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi.tr_TR
dc.contributor.orcid0000-0002-2325-7728tr_TR
dc.identifier.startpage270tr_TR
dc.identifier.endpage276tr_TR
dc.identifier.volume33tr_TR
dc.identifier.issue4tr_TR
dc.relation.journalPresse Medicaleen_US
dc.contributor.buuauthorTamgaç, Feyzi-
dc.relation.collaborationYurt dışıtr_TR
dc.identifier.pubmed15029020tr_TR
dc.subject.wosMedicine, general and internalen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ4en_US
dc.contributor.scopusid35569192500tr_TR
dc.subject.scopusLymph Node Dissection; Seminoma; Testicular Germ Cell Tumoren_US
dc.subject.emtreeCancer chemotherapyen_US
dc.subject.emtreeCancer scintiscanningen_US
dc.subject.emtreeCancer stagingen_US
dc.subject.emtreeDiagnostic accuracyen_US
dc.subject.emtreeDiagnostic erroren_US
dc.subject.emtreeDiagnostic imagingen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeImaging systemen_US
dc.subject.emtreeLymph node metastasisen_US
dc.subject.emtreeParameteren_US
dc.subject.emtreePositron emission tomographyen_US
dc.subject.emtreePrognosisen_US
dc.subject.emtreeReviewen_US
dc.subject.emtreeTestis canceren_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeFluorodeoxyglucose F 18en_US
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.